See from oost 822 that it is.... Wow |
Is it till the end of January purchases to be made by? |
I think you are reading it right..these could easily be walked up if Winterflood push the pedal, if no meaningful seller emerges then should move higher..imagine it is in Wins interest to get it done. |
So to be clear.
CRS have £5,000,000 to (possibly) deploy in the next 30 or so trading days.
So far today we have had 40,000 shares traded. approx £26,000
13 trades.. of which 4 were me buying.
It'll be interesting to see what happens to the share price once the £5m gets rolling.
Good luck holders :) |
Gem
Think the market hasn't read the RNS through properly.
My take is winterflood can buy as many shares as they like - so long as it is not at a higher price than an independent buy.
To me this put a solid floor under the share price.
Where's the risk. |
The stock market has been on a tear over the last month on hopes for a dovish pivot from the Fed, but investors like me have seen this movie before whereby i'm left pondering if to sell off 30% of my $450k portfolio which comprised of plummeting stocks or hold on. |
Referencing Morphic Medical , the developed world needs a multi pronged approach both medicinal and physical to deal with growing health issues associated with obesity.Cost to UK alone is a massive issue and it would appear highly cost effective to employ non surgical intervention.https://www.theguardian.com/society/2023/dec/04/cost-of-people-being-overweight-in-uk-now-98bn-study-findsFirst time i have looked through the Morphic website ..definitely an upgrade on the product and market opportunity.https://morphicmedical.com/Uk diabetes' rates https://www.theguardian.com/society/2023/apr/13/uk-in-rapidly-escalating-diabetes-crisis-as-cases-top-5m-report-saysThough the scale of the problem here is dwarfed by some other surprising countries..it's a growing global issue. https://www.diabetes.co.uk/news/2023/jun/countries-with-highest-number-of-diabetes-cases-unveiled.html |
Good move, buying back nearly 10 percent of company 👍
Surprised not more buying in today |
Looks to me like the co. putting a concrete floor under the share price.. should create a sort of ratcheting-up of the price.
👍 |
If CA cannot get an exit on at least one of the four hopeful prospects at ALM, they risk being diluted by cash calls to the point where the cost of keeping the ALM holding becomes more than it's worth. That is the problem, and one Sam Dobbyn was sent in to avoid. It is a bit too early to throw in the towel but there needs to be some concrete news next year. (I'll give Dobbyn 2024. Meanwhile a response to his bosses might be wise ...) |
If only ALM had managed to monetise investments and return funds to shareholder as CRS have...unfortunately it seems to go from bad to worse there...luckily now a very small investment to CRS. |
Saba still have a big interest in a company that (supposedly) trades at a >30% discount to its NAV.
If CA are right that Mystic Med could have a valuation of 40 million plus, then they should stick around.
I was hoping for rumours of ALM's investor meeting, but ... |
Clear that Saba again tried to throw their weight around to get something and exert control...again it seems that they do not have the controlling interest they would like. The company has done well in returning value to holders since Saba surfaced and wanted it wound up , if it had been done as a fire sale other shareholders would have suffered value destruction. So pleased to see that Saba are unable to force their will on the running of the company by voting down directors..likely will get back in their cage again realising this. |
Result of the AGM RNS issued at 10:50 AM. Worth quoting:
The Board of the Fund notes the votes of more than 20% against resolutions 2, 3, 5, 6, 7 and 9. The Board is committed to continuing an open dialogue with the Company's shareholders. Where it is able to, the Board will continue to seek to engage with those shareholders who are understood to have voted against the resolutions to understand their views or any specific concerns. The Board will update shareholders on this and actions taken within six months.
So, far from straightforward. The 99% approvals were for approving Auditors Report and their remuneration to be set by the Board. The Resolutions mentioned above only supported by 65% were about re-appointing directors Waldron, Hervouet and LeMaitre and their remuneration being set by the board.
Also the resolution to buy shares up to 15% of shares in issue only had 75% in favour. |
I guess one issue is, anything UK listed is likely to be on a low rating... |
UBG ... interesting shout. Not sure what caused them to miss their deadline, nor what Transaction they have been hoping for.
You'd need something without any creditors of any legitimacy. That limits the field. |
Mine is CNSL |
Such as UBG? |
Finally some share price interest ahead of AGM which may update on Morphic. I would like to see Morphic acquire a zombie company for a listing (I have one in mind that would suit, but there must be many after Covid chaos in Downing Street). Then they could wind down quickly. We'll see on Wednesday. |
A dwindling pot of assets and high management fees .... PIs won't have much say ... don't get caught out :-( |
Following further investment of GBP8.3 million in Morphic Medical since the beginning of 2022 and combined with cash returns of 55p a share, Morphic Medical now accounts for 40 per cent of net asset value. |
The nhs is widening its non invasive treatments this news from a few weeks ago is a similar type procedure that is just being adopted , im unsure of the pros and cons of the different approaches but there appears increased demand for non medicinal approach to obesity.https://news.sky.com/story/90-minute-accordion-procedure-safe-and-effective-way-for-nhs-to-tackle-obesity-12971357I think this news is a positive for Morphic Medical personally. They have a product , there is a market ..can they sell it ? |
Ozempic costs about $900 for a one-month supply. |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
